Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Dec 20;36(10):991–999. doi: 10.1200/JCO.2017.75.7310

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 by American Society of Clinical Oncology

PMC Copyright notice

Fig A1. — Progression-free survival (PFS) in patients with metastatic castration-resistant prostate cancer treated with abiraterone (A) or abiraterone plus veliparib (A + V) and stratified by ETS gene fusion status. (A) PFS curves are shown for all 148 response-evaluable patients treated with abiraterone/prednisone alone (n = 72) or in combination with veliparib (n = 76). (B) PFS curves are shown for each treatment arm stratified by ETS gene fusion status (determined by immunohistochemistry or in situ hybridization).